Ascendis Pharma A/S (NASDAQ:ASND) Earns “Outperform” Rating from Wedbush

Wedbush reissued their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research note issued to investors on Friday morning, Marketbeat.com reports. Wedbush currently has a $181.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on ASND. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. StockNews.com downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, November 12th. Oppenheimer restated an “outperform” rating and set a $190.00 price objective (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. Wells Fargo & Company upped their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Finally, Citigroup lifted their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

Shares of ASND stock opened at $126.51 on Friday. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The firm has a market cap of $7.67 billion, a PE ratio of -15.66 and a beta of 0.66. The stock has a 50 day moving average of $132.30 and a 200-day moving average of $132.60.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. As a group, equities analysts predict that Ascendis Pharma A/S will post -7.3 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of Ascendis Pharma A/S in the 1st quarter worth approximately $288,000. ProShare Advisors LLC increased its holdings in Ascendis Pharma A/S by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after purchasing an additional 361 shares in the last quarter. Acadian Asset Management LLC raised its position in Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after purchasing an additional 234,446 shares during the last quarter. Bessemer Group Inc. boosted its stake in Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Finally, Nan Fung Group Holdings Ltd acquired a new position in Ascendis Pharma A/S in the first quarter worth $2,056,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.